What Is Adamax?

Adamax is a commercial name used for a modified analogue of Semax, the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro.

The compound appears to have originated in the designer-peptide market rather than through a conventional academic or pharmaceutical-development program. Public descriptions usually claim two changes to Semax:

• N-terminal acetylation
• A C-terminal adamantane-derived residue or group, often described as analogous to the terminal modification used in P021

Identity and Nomenclature Conflicts

Most commonly repeated identity

Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AG-NH₂

The abbreviation AG is commonly described as an adamantane-containing amino-acid residue related to the C-terminal modification of P021.

Alternative commercial descriptions

• Ac-MEHFPGP-adamantane
• Ac-MEHFPGP-[adamantane cage]-CONH₂
• Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-OH
• Unmodified MEHFPGP, which is simply Semax

Conflicting formulas and masses

Public sellers report formulas and molecular weights that cannot all describe the same molecule.

Conclusion

“Adamax” cannot be authenticated by name alone. Every batch requires complete structural disclosure and orthogonal analytical confirmation.

🧬 Proposed Molecular Structure

Semax parent sequence

H-Met-Glu-His-Phe-Pro-Gly-Pro-OH

One-letter notation: MEHFPGP

Most frequently proposed Adamax notation

Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AG-NH₂

Why “AG” is ambiguous

In this context, AG does not simply mean alanine-glycine. It is usually intended to denote a noncanonical adamantane-derived amino-acid residue resembling the C-terminal amino-adamantane modification found in P021. A complete structure must specify:

• The precise adamantane scaffold
• The carbon bearing the amino and amide groups
• Stereochemistry
• Linker length
• Attachment to the terminal proline
• Whether the final carboxyl group is amidated

⚛️ Molecular Weight and 🧫 Formula

📅 Discovery Timeline and Research History

1980s: Semax developed

Semax was developed in Russia from the ACTH(4–7) sequence extended with Pro-Gly-Pro to improve stability and preserve neuroactive properties without corticosteroid activity.

1990s–2010s: Semax research expands

Studies examined learning, memory, ischemic injury, gene expression, neurotrophic factors, monoamines, inflammation, and human functional connectivity.

2010s: P021 developed

P021 was developed from a CNTF-derived tetrapeptide and modified with an adamantane-based residue to improve metabolic stability and brain availability in experimental models.

Before 2018: Adamax appears in designer-peptide market

Adamax is commonly attributed to the former commercial research company Ceretropic. No original peer-reviewed synthesis or pharmacology paper was identified.

2025: Regulatory attention

Adamax was identified in regulatory discussions concerning unscheduled peptides and designer products in New Zealand.

2025–2026: Commercial availability expands

Multiple suppliers list Adamax with inconsistent structures, formulas, and claimed mechanisms.

Current status

No direct Adamax publication, clinical trial, validated pharmacology program, or standardized compendial identity was identified.

Relationship to Semax and ACTH Fragments

Semax sequence

Semax is the heptapeptide:

Met-Glu-His-Phe-Pro-Gly-Pro

ACTH origin

The first four residues—Met-Glu-His-Phe—correspond to ACTH(4–7). The Pro-Gly-Pro tail was added to improve metabolic resistance.

Semax research themes

• Ischemic-brain injury
• Learning and memory
• BDNF and neurotrophin signaling
• Monoamine regulation
• Gene-expression changes
• Inflammatory and vascular responses

Adamax modifications

Adamax is claimed to preserve the Semax core while adding terminal modifications intended to increase stability and lipophilicity.

Why direct testing is required

N-terminal acetylation and a large C-terminal noncanonical residue may alter peptide conformation, target binding, enzymatic cleavage, solubility, distribution, and toxicity.

Relationship to P021 and Adamantane Chemistry

What P021 is

P021 is a modified peptide derived from a short ciliary neurotrophic factor sequence. Its adamantane-derived terminal residue was designed to improve stability and central exposure.

Adamax design claim

Adamax is commonly described as combining an N-acetyl Semax backbone with the adamantane-containing terminal chemistry of P021.

Adamantane medicinal chemistry

Adamantane is a rigid, hydrophobic cage used in several approved drugs and experimental compounds. It can alter:

• Lipophilicity
• Protein binding
• Membrane association
• Metabolic stability
• Tissue retention
• Off-target pharmacology

Not automatically brain penetrant

An adamantane group can improve brain exposure in some molecules but worsen solubility or transport in others. Human or animal pharmacokinetic measurements are required.

P021 evidence is not Adamax evidence

Even if Adamax uses the same terminal residue, the much larger Semax backbone creates a different molecule.

🧠 Proposed Mechanism of Action

No direct Adamax mechanism has been established. The following pathways are hypotheses based on Semax and P021.

1. Neurotrophin signaling

Semax research reports changes in BDNF, NGF, and related gene expression. Adamax has not been directly tested.

2. Trk receptor pathways

Commercial pages claim improved TrkB sensitivity, but no direct Adamax receptor-binding or phosphorylation study was identified.

3. Gene-expression modulation

Semax changes expression of genes involved in immune, vascular, and neuronal pathways after ischemia. Chemical modification may change this profile.

4. Monoamine systems

Semax affects dopamine, serotonin, and norepinephrine-related signaling in selected models. Adamax data are absent.

5. Protease resistance and distribution

N-acetylation, C-terminal amidation, and a bulky adamantane-derived residue could reduce enzymatic degradation, but this remains unmeasured.

🎯 Receptor and Pathway Profile

BDNF, TrkB, and Neurotrophic Claims

Semax evidence

Semax has been associated with increased BDNF expression or concentration in selected animal and human stroke-related studies.

BDNF biology

BDNF supports neuronal survival, synaptic plasticity, learning, and adaptation through TrkB and other signaling systems.

Adamax claims

Suppliers commonly claim that Adamax increases BDNF and improves TrkB receptor sensitivity more strongly than Semax.

Missing evidence

No Adamax dose-response, BDNF assay, TrkB phosphorylation study, receptor-binding experiment, or comparative Semax study was identified.

More BDNF is not always better

Neurotrophin effects depend on brain region, timing, injury, receptor balance, dose, and disease state.

Cognition, Memory, and Plasticity Claims

Semax learning research

Semax improved learning, memory, and attention in selected animal and regional human studies.

Functional-connectivity study

A study in 52 healthy participants examined resting-state brain connectivity after Selank and Semax.

Adamax evidence

No controlled Adamax memory, attention, executive-function, long-term-potentiation, synaptogenesis, or neurogenesis study was found.

Subjective reports are not clinical trials

Online anecdotes about focus, stimulation, endurance, or mental clarity cannot determine efficacy, dose-response, or safety.

No proven cognitive enhancer

Adamax has not been shown to improve cognition in healthy people, older adults, dementia, ADHD, brain injury, or neurodegenerative disease.

Neuroprotection and Ischemia Claims

Semax ischemia research

Semax has demonstrated neuroprotective and gene-expression effects in experimental cerebral ischemia and has regional clinical use in Russia.

Adamax extrapolation

Commercial sources infer that a longer-lasting Semax analogue should provide stronger neuroprotection.

No Adamax ischemia study

No direct infarct-volume, neuronal-survival, cerebral-blood-flow, oxidative-stress, apoptosis, excitotoxicity, or functional-recovery study was identified.

Not a stroke treatment

Adamax must not be presented as a substitute for emergency stroke evaluation, thrombolysis, thrombectomy, antiplatelet therapy, rehabilitation, or standard secondary prevention.

Monoamine and Stress-Response Claims

Semax monoamine research

Semax altered dopamine, serotonin, and norepinephrine-related measures in selected animal models.

Stress and anxiety effects

Some studies report changes in anxiety-like behavior and stress responses after Semax.

Adamax evidence gap

No direct Adamax microdialysis, receptor-binding, transporter, behavioral, or stress-hormone study was identified.

Stimulatory claims

Supplier and community reports describe Adamax as more stimulating than Semax, but such reports cannot establish pharmacology or safety.

Potential interaction uncertainty

Interactions with stimulants, antidepressants, antipsychotics, MAO inhibitors, sedatives, anticonvulsants, or recreational substances are unknown.

Direct Evidence and Major Limitations

No primary Adamax study identified

Searches of PubMed and PubMed Central did not identify a distinct Adamax pharmacology or clinical paper.

No standardized identity

Suppliers report mutually incompatible formulas, molecular weights, and sequences.

No validated pharmacokinetics

Half-life, nasal bioavailability, plasma exposure, brain exposure, metabolism, tissue distribution, and excretion are unknown.

No toxicology package

Acute, repeated-dose, genotoxic, reproductive, developmental, immunotoxic, cardiac, and neurobehavioral safety studies were not identified.

No validated potency assay

There is no accepted test linking Adamax batch quality to BDNF, TrkB, memory, or neuroprotection.

Designer-product risk

Commercial availability can precede scientific characterization, creating a high risk of incorrect identity and unsupported claims.

Safety and Regulatory Considerations

Unknown human safety

No controlled human dose-ranging or adverse-event study was identified.

Unknown central nervous system effects

Potential agitation, insomnia, anxiety, mood changes, headaches, blood-pressure effects, seizures, or cognitive impairment have not been systematically assessed.

Unknown drug interactions

Potential interactions with psychiatric, neurologic, cardiovascular, and stimulant medications are unknown.

Adamantane-related uncertainty

A bulky hydrophobic modification may alter tissue accumulation, renal or hepatic clearance, membrane interactions, and off-target binding.

Methionine oxidation

The N-terminal methionine in the Semax core is susceptible to oxidation, creating a distinct impurity with potentially altered activity.

Nasal-formulation risks

Finished nasal products require control of microbial quality, pH, osmolality, preservatives, delivered dose, plume geometry, droplet size, and mucosal toxicity.

Regulatory status

Adamax is not FDA approved and has no recognized approved indication.

🧪 Laboratory Testing Methods

📄 How to Interpret an Adamax COA

1. Demand a complete chemical drawing: “Adamax” or “AG” alone is inadequate.
2. Verify the core sequence: Met-Glu-His-Phe-Pro-Gly-Pro.
3. Confirm N-terminal acetylation: This must be demonstrated separately.
4. Identify the exact terminal adamantane residue: Structure, linker, attachment, stereochemistry, and amidation are required.
5. Reject contradictory formula and mass data: The reported structure, HRMS result, and theoretical formula must agree.
6. Use MS/MS and NMR: HPLC purity alone cannot prove Adamax identity.
7. Measure net content: Area purity is not the labeled milligram amount.
8. Review free Semax, methionine sulfoxide, incomplete modifications, free adamantane reagent, water, salts, and residual solvents.
9. For nasal products, require finished-product data: Dose uniformity, microbial quality, preservative effectiveness, spray performance, pH, and osmolality.
10. Do not infer biological efficacy: A COA cannot prove BDNF induction, TrkB activation, brain penetration, memory enhancement, neuroprotection, endurance, or longer duration.

📊 Adamax vs Semax vs N-Acetyl Semax Amidate

Adamax vs P021

Adamax vs Dihexa vs FGL vs DNSP-11

Adamax vs Evidence-Based Cognitive and Neurologic Care

🔗 Related Peptides and Pathways

• Semax: Defined MEHFPGP parent peptide.
• ACTH(4–7): Met-Glu-His-Phe core from which Semax was designed.
• Pro-Gly-Pro: C-terminal glyproline motif added to Semax.
• P021: CNTF-derived peptide containing a published adamantane-based modification.
• BDNF and TrkB: Semax-associated pathways claimed—but not proven—for Adamax.
• NGF: Another neurotrophin discussed in Semax literature.
• Monoamines: Dopamine, serotonin, and norepinephrine systems studied with Semax.
• Adamantane: Hydrophobic medicinal-chemistry scaffold claimed in Adamax.

🖼️ Original Diagram Specifications

Diagram 1: Adamax identity tree

Show Semax as the parent molecule branching into N-acetyl Semax, N-acetyl Semax amidate, proposed Adamax with an adamantane-derived residue, and mislabeled unmodified Semax products.

Diagram 2: Complete versus incomplete notation

Contrast the shorthand Ac-MEHFPGP-AG-NH₂ with a fully specified atom-level structure, highlighting the missing definition of AG.

Diagram 3: Semax–P021 hybrid concept

Show the Semax backbone joined conceptually to the terminal adamantane chemistry of P021, with a warning that shared substructures do not confer shared evidence.

Diagram 4: Hypothetical pharmacokinetic changes

Show how acetylation, amidation, and adamantane conjugation could alter proteolysis, solubility, membrane binding, clearance, and CNS exposure.

Diagram 5: Claimed neurotrophic pathway

Show BDNF, TrkB, synaptic plasticity, memory, and neuronal survival, with every Adamax arrow labeled “unverified extrapolation.”

Diagram 6: Evidence ladder

Show commercial claim, structural confirmation, in vitro pharmacology, animal PK/toxicology, controlled human trials, and regulatory approval.

Diagram 7: COA workflow

Show full structural disclosure, HRMS, MS/MS, NMR, chiral analysis, methionine oxidation, modifier impurities, net content, nasal testing, and stability.

❓ Frequently Asked Questions

Is Adamax a peptide?

It is marketed as a modified Semax peptide analogue, but its exact standardized identity is unresolved.

What is Adamax’s sequence?

The most common notation is Ac-MEHFPGP-AG-NH₂, but AG is often not chemically defined.

What does AG mean?

It is generally intended to represent an adamantane-derived amino-acid residue related to P021, not ordinary alanine-glycine.

What is its molecular formula?

No universally verified formula exists. Public sources report mutually incompatible formulas.

What is its molecular weight?

Commercial listings range from roughly 719.8 to 1032.2 g/mol, demonstrating unresolved identity.

Is Adamax the same as Semax?

No. Adamax is claimed to be an acetylated, adamantane-modified Semax analogue.

Is Adamax FDA approved?

No.

Has Adamax been studied in humans?

No direct peer-reviewed human study was identified.

Does Adamax increase BDNF?

This is extrapolated from Semax research. No direct Adamax BDNF study was identified.

Does it activate TrkB?

No direct Adamax TrkB-binding or signaling study was identified.

Does it improve memory?

No controlled Adamax memory study was identified.

Does it cross the blood–brain barrier?

Unknown. No direct brain-exposure pharmacokinetic study was identified.

Is the adamantane group automatically beneficial?

No. It may improve stability or distribution but can also reduce solubility or create new off-target effects.

Does 99% HPLC prove Adamax identity?

No. A full structure, HRMS, MS/MS, NMR, and suitable reference standards are required.

Final Thoughts

Adamax should currently be described as an unstandardized designer Semax analogue rather than a well-characterized neuroprotective or cognitive peptide. The original draft incorrectly presented neurotrophic, BDNF, synaptic-plasticity, oxidative-stress, apoptosis, memory, and neurodegenerative-disease claims as though they came from direct Adamax studies.

The available evidence supports a narrower conclusion: Semax and P021 each have separate preclinical research records, while Adamax appears to combine structural concepts from both without a direct published pharmacology or safety program.

The first requirement for credible Adamax research is unambiguous chemical identity. This must be followed by validated analytical methods, pharmacokinetics, brain-distribution measurements, receptor and signaling studies, toxicology, and controlled human research before cognitive or therapeutic claims can be supported.

📚 References

1. Ashmarin IP, et al. Semax, an analogue of ACTH(4–10), is a potential agent for the treatment of ischemic stroke. 2006.
2. Dergunova LV, et al. Neuroprotective Peptides and New Strategies for Ischemic Stroke Therapy. 2023.
3. Medvedeva EV, et al. The peptide Semax affects expression of genes related to immune and vascular systems in rat brain after ischemia. 2014.
4. Glazova NY, et al. Semax attenuates behavioral and monoamine alterations in rats. 2021.
5. Lebedeva IS, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. 2020.
6. Ashmarin IP, et al. Natural and hybrid stable regulatory glyproline peptides. 2005.
7. Dolotov OV, et al. Semax and BDNF expression in experimental brain ischemia. Bulletin of Experimental Biology and Medicine.
8. Agapova TY, et al. Semax effects on neurotrophin expression in rat brain. Molecular Biology.
9. Medvedeva EV, et al. Semax transcriptomic effects after cerebral ischemia. BMC Genomics and related literature.
10. Storozhevykh TP, et al. Semax and neuronal survival under glutamate toxicity. Bulletin of Experimental Biology and Medicine.
11. Shadrina MI, et al. Semax effects on dopamine and serotonin systems. Neuroscience and Behavioral Physiology.
12. Manchenko DM, et al. Semax and learning in animal models. Bulletin of Experimental Biology and Medicine.
13. Myasoedov NF, et al. Semax design and ACTH-derived peptide research. Russian Journal of Bioorganic Chemistry.
14. Vanhee C, et al. The occurrence of putative cognitive enhancing research peptides in products available on the internet. 2020.
15. New Zealand Medicines and Medical Devices Safety Authority. Classification of Unscheduled Peptides. Medicines Classification Committee submission. 2025.
16. Peptide 021 chemical and preclinical literature concerning CNTF-derived neurotrophic peptide analogues.
17. Chohan MO, et al. P021, a CNTF-derived peptide, enhances neurogenesis and cognition in animal models. Journal of Alzheimer's Disease.
18. Baazaoui N, et al. P021 effects on tau pathology and cognition in transgenic mouse models. Journal of Alzheimer's Disease.
19. Li B, et al. P021 and neurogenesis in aged and Alzheimer-like animals. Neurobiology of Aging.
20. Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chemical Reviews.
21. Liu J, et al. The many faces of the adamantyl group in drug design. European Journal of Medicinal Chemistry.
22. Lamoureux G, Artavia G. Use of the adamantane structure in medicinal chemistry. Current Medicinal Chemistry.
23. Pardridge WM. Blood–brain barrier drug targeting. NeuroRx.
24. Begley DJ. Delivery of therapeutic peptides to the central nervous system. Pharmaceutical Research.
25. Di L, Kerns EH. Blood–brain barrier in drug discovery. Drug Discovery Today.
26. Wang CK, Craik DJ. Designing peptide therapeutics for membrane permeability. Nature Chemical Biology.
27. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives and current development trends. Bioorganic & Medicinal Chemistry.
28. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today.
29. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chemical Biology & Drug Design.
30. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today.
31. Park JW, et al. Methionine oxidation in therapeutic peptides and proteins. Pharmaceutical Research.
32. Manning MC, et al. Stability of protein pharmaceuticals. Pharmaceutical Research.
33. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
34. International Council for Harmonisation. ICH Q3A and Q3B: Impurities in New Drug Substances and Products.
35. International Council for Harmonisation. ICH Q3C: Residual Solvents.
36. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
37. International Council for Harmonisation. ICH M10: Bioanalytical Method Validation.
38. United States Pharmacopeia General Chapter <621>: Chromatography.
39. United States Pharmacopeia General Chapter <71>: Sterility Tests.
40. United States Pharmacopeia General Chapter <85>: Bacterial Endotoxins Test.
41. United States Pharmacopeia General Chapter <51>: Antimicrobial Effectiveness Testing.
42. FDA guidance concerning nasal spray and inhalation solution, suspension, and spray drug products.
43. European Pharmacopoeia guidance concerning nasal preparations and peptide quality.
44. Public Adamax commercial listings reviewed solely to document conflicts in proposed sequence, formula, and molecular weight; these are not evidence of efficacy or validated identity.

Adamax identity, Semax parent evidence, P021-related adamantane chemistry, commercial specification conflicts, safety uncertainty, and analytical requirements were reviewed in July 2026. No direct peer-reviewed Adamax pharmacology or clinical study was identified.